01 — The Text
What.
- Streamlines FDA approval process for biosimilars—cheaper drug versions of expensive biologics already on market.
- Likely reduces paperwork and timelines for manufacturers seeking biosimilar clearance.
- Detailed specifics pending official CRS summary publication; bill text amendments suggest procedural changes to expedite reviews.
02 — The Stakes
So what?
- Patients win: faster access to lower-cost alternatives to high-priced biologic drugs (cancer treatments, immunosuppressants, biologics avg $100k+/year).
- Drug manufacturers gain: clearer pathway to market entry, reducing development costs.
- Brand-name biologics makers lose exclusivity period protection; drugmakers' patent incentives weaken slightly.
03 — The Path
Now what?
- Senate committee approved it (July 2026) with amendments; now on legislative calendar awaiting full Senate floor vote—not yet scheduled.
- Only 2 cosponsors signals modest bipartisan support but not urgent priority.
- Track progress at Congress.gov; contact your senator if cost of biologics affects you or your family.
Legislative History
Actions.
- Jul 27, 2026 — Placed on Senate Legislative Calendar under General Orders. Calendar No. 520.
- Jul 27, 2026 — Committee on Health, Education, Labor, and Pensions. Reported by Senator Cassidy with an amendment in the nature of a substitute. Without written report.
- Jul 27, 2026 — Committee on Health, Education, Labor, and Pensions. Reported by Senator Cassidy with an amendment in the nature of a substitute. Without written report.
- Jul 22, 2026 — Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.
- Apr 10, 2025 — Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- Apr 10, 2025 — Introduced in Senate